

DAFTAR PUSTAKA

- Alves, C., Mendes, D., dan Marques, F.B., 2019. Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis. *European Journal of Clinical Pharmacology*, **75**: 1431–1443.
- Ansari, J., 2010. Drug interaction and pharmacist. *Journal of Young Pharmacists*, **2**: 326–331.
- Awdisma, W.M., Nosa, U.S., Hasmono, D., dan Nurmainah, N., 2021. Kajian Literatur: Tinjauan Remdesivir sebagai Pilihan Terapi pada COVID-19. *Jurnal Pharmascience*, **8**: 121.
- Awortwe, C. dan Cascorbi, I., 2020. Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions. *Pharmacological Research*, **161**: 105250.
- Badan Pengawas Obat dan Makanan, 2021. *Informatorium Obat COVID-19 Di Indonesia*, 3rd ed. BPOM, Jakarta.
- Baggio, D. dan R Ananda-Rajah, M., 2021. Fluoroquinolone antibiotics and adverse events. *Australian Prescriber*, **44**: 161–164.
- Baihaqi, F.A. dan Rumaropen, H., 2022. Faktor-Faktor yang Berhubungan dengan Lama Rawat Inap Pasien COVID-19 di RSUD Serui Provinsi Papua: Studi Potong Lintang. *Jurnal Penyakit Dalam Indonesia*, **8**: 187.
- Bajgain, K.T., Badal, S., Bajgain, B.B., dan Santana, M.J., 2021. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. *American Journal of Infection Control*, **49**: 238–246.
- Baxter, K., 2010. *Stockley 's Drug Interactions*, Ninth. ed. Pharmaceutical press, United States of American.
- Bjerrum, L., Lopez-Valcarcel, B.G., dan Petersen, G., 2008. Risk factors for potential drug interactions in general practice. *European Journal of General Practice*, **14**: 23–29.
- Cattaneo, D., Pasina, L., Maggioni, A. Pietro, Giacomelli, A., Oreni, L., Covizzi, A., dkk., 2020. Drug–Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. *Drugs and Aging*, **37**: 925–933.
- Chen, C., Zhou, W., Fan, W., Ning, X., Yang, S., Lei, Z., dkk., 2021. Association of anemia and COVID-19 in hospitalized patients. *Future Virology*, **16**: 459–466.
- Cucinotta, D. dan Vanelli, M., 2020. WHO declares COVID-19 a pandemic. *Acta Biomedica*, **91**: 157–160.
- Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N.,

- dkk., 2020. Coronavirus diseases (COVID-19) current status and future perspectives: A narrative review. *International Journal of Environmental Research and Public Health*, **17**: 2690.
- Ejaz, H., Alsrhani, A., Zafar, A., Javed, H., Junaid, K., Abdalla, A.E., dkk., 2020. COVID-19 and comorbidities: Deleterious impact on infected patients. *Journal of Infection and Public Health*, **13**: 1833–1839.
- Fang, L., Karakiulakis, G., dan Roth, M., 2020. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *The Lancet Respiratory Medicine*, **8**: e21.
- Food and Drug Administration, 2022. 'FACT SHEET FOR HEALTHCARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF VEKLURY® (remdesivir)', U.S. Department of Health and Human Services. URL: <https://www.fda.gov/media/137566/download>.
- Grasselli, G., Pesenti, A., dan Cecconi, M., 2020. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast during an Emergency Response. *JAMA - Journal of the American Medical Association*, **323**: 1545–1546.
- Hansten, P.D., 2003. Drug interaction management. *Pharmacy World and Science*, **25**: 94–97.
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., dkk., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*, **395**: 497–506.
- Ilpaj, S.M. dan Nurwati, N., 2020. Analisis Pengaruh Tingkat Kematian Akibat Covid-19. *Jurnal Pekerjaan Sosial*, **3**: 16–28.
- Iswahyuni, S., Sayekti, S., Sunaryati, H., Widiyanto, A., Darmayanti, A.T., Atmojo, T., dkk., 2021. Jurnal Ilmiah Permas : Jurnal Ilmiah STIKES Kendal **11**: 247–254.
- Kearon, C., Johnston, M., Moffat, K., McGinnis, J., dan Ginsberg, J.S., 1998. Effect of Warfarin on Activated Partial Thromboplastin Time in Patients Receiving Heparin. *Archives of Internal Medicine*, **158**: 1140.
- Kemenkes, 2022. Coronavirus Disease Coronavirus Disease (COVID-19) Spreads. *Who*, **75**: 95–97.
- Kementerian Kesehatan Republik Indonesia, 2021. Keputusan menteri kesehatan republik indonesia nomor hk.01.07/menkes/5671/2021 tentang manajemen klinis tata laksana **3**: 1–106.
- Khaerunnisa, R., Aula Rumana, N., Yulia, N., dan Fannya, P., 2022. Gambaran Karakteristik Pasien Covid-19 di Rumah Sakit Mekar Sari Bekasi Tahun 2020–2021. *Jurnal Manajemen Informasi Kesehatan Indonesia*, **10**: 64–72.
- Klein, S.L. dan Flanagan, K.L., 2016. Sex differences in immune responses. *Nature*

Reviews Immunology, **16**: 626–638.

Kusumawardani, L.A., Maria, N., dan Fanani, Y.N., 2021. Potential drug interactions analysis of COVID-19 patients at a hospital in West Java. *Jurnal Ilmiah Farmasi*, **17**: 181–196.

Latulola, S.M. dan Lefrandt, R.L., 2013. TORSADE DE POINTES. *JURNAL BIOMEDIK (JBM)*, **4**: 126–135.

Leekha, S., Terrell, C.L., dan Edson, R.S., 2011. General Principles of Antimicrobial Therapy. *Mayo Clinic Proceedings*, **86**: 156–167.

Lemeshow, S., Klar, J., Lwanga, stephen K., Pramono, D., dan Hosmer, D.W., 1997. *Besar Sampel Dalam Penelitian Kesehatan*. Gadjah Mada University Press, Yogyakarta.

Lisni, I., Mujianti, D., dan Anggriani, A., 2021. Antibiotic Profile For Covid-19 Treatment In A Hospital In Bandung. *Jurnal Ilmiah Farmako Bahari*, **12**: 99–106.

Manjhi, P.K., Kumar, R., Priya, A., dan Rab, I., 2021. Drug-Drug Interactions in Patients with COVID-19: A Retrospective Study at a Tertiary Care Hospital in Eastern India. *Maedica*, **16**: 163–169.

Maulidia, S.S., Mahmudah, F., dan Sastyarina, Y., 2021. Kajian Potensi Interaksi Obat pada Pasien COVID-19 di Rumah Sakit X Kota Samarinda. *Proceeding of Mulawarman Pharmaceuticals Conferences*, **14**: 295–301.

Mehlhorn, A.J. dan Brown, D.A., 2007. Safety Concerns with Fluoroquinolones. *Annals of Pharmacotherapy*, **41**: 1859–1866.

Menkes RI, 2021. PERATURAN MENTERI KESEHATAN REPUBLIK INDONESIA NOMOR 26 TAHUN 2021 TENTANG PEDOMAN INDONESIAN CASE BASE GROUPS (INA-CBG) DALAM PELAKSANAAN JAMINAN KESEHATAN. *Kementerian Kesehatan Republik Indonesia*, 56.

Moon, J., Davison, A., dan Bandy, B., 1992. Vitamin D and aluminum absorption. *CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne*, **147**: 1308, 1313.

Mouri, Mi. dan Badireddy, M., 2022. 'Hyperglycemia', *StatPearls [Internet]*. URL: <https://www.ncbi.nlm.nih.gov/books/NBK430900/>.

Mukherjee, S. dan Pahan, K., 2021. Is COVID-19 Gender-sensitive? 38–47.

National Institutes of Health, 2021. 'Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19)', *NIH*. URL: <https://www.covid19treatmentguidelines.nih.gov/> (diakses tanggal 10/11/2021).

Newton, D.W., 2009. Drug incompatibility chemistry. *American Journal of Health-*

System Pharmacy, **66**: 348–357.

Novita, N.F. dan Destiani, D.P., 2019. Interaksi Obat terhadap Perpanjangan Interval QT. *Farmaka*, **18**: 110–118.

PDPI, PERKI, PAPDI, PERDATIN, dan IDAI, 2020. *Pedoman Tatalaksana COVID-19 Edisi 3 Desember 2020*, Pedoman Tatalaksana COVID-19.

PDPI, PERKI, PAPDI, PERDATIN, dan IDAI, 2022. *Pedoman Tatalaksana COVID-19 Edisi 4*, 4th ed, Pedoman Tatalaksana COVID-19.

Pemerintah Daerah Kabupaten Kebumen, 2022. 'DATA PANTAUAN COVID-19 KABUPATEN KEBUMEN', corona.kebumenkab.go.id. URL: <https://corona.kebumenkab.go.id/> (diakses tanggal 8/7/2022).

PERKENI, 2021. *Pedoman Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Dewasa Di Indonesia*. Perkumpulan Endokrinologi Indonesia, Jakarta.

Putri, W.A. dan Dian A, T., 2021. Gambaran Pengobatan Pasien Suspek Covid-19 Rawat Inap RS Brayat Minulya Surakarta Periode Maret–Oktober 2020. *Ejournal.Ijmsbm.Org*, **8**: 111–118.

Ramadhan, P., 2020. Diagnosis covid-19. *Osf.Io*, 1–50.

Rashedi, J., Poor, B.M., Asgharzadeh, V., Pourostadi, M., Kafil, H.S., Vegari, A., dkk., 2020. Risk factors for covid-19. *Infezioni in Medicina*, **28**: 469–474.

Rotter, T., Kinsman, L., James, E.L., Machotta, A., Gothe, H., Willis, J., dkk., 2010. Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. *Cochrane Database of Systematic Reviews*, **17**: .

Russell, C.D., Millar, J.E., dan Baillie, J.K., 2020. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *The Lancet*, **395**: 473–475.

Sanyaolu, A., Okorie, C., Marinkovic, A., Patidar, R., Younis, K., Desai, P., dkk., 2020. Comorbidity and its Impact on Patients with COVID-19. *SN Comprehensive Clinical Medicine*, **2**: 1069–1076.

Schiffrin, E.L., Flack, J.M., Ito, S., Muntner, P., dan Webb, R.C., 2020. Hypertension and COVID-19. *American Journal of Hypertension*, **33**: 373–374.

Scott, A.G. dan Scott, G.N., 2013. Mechanisms of drug interactions. I. *Pharmacy Tech Topics*, **18**: 4–5.

Singh, A.K., Gupta, R., Ghosh, A., dan Misra, A., 2020. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, **14**: 303–310.

Singhal, T., 2020. Review on COVID19 disease so far. *The Indian Journal of Pediatrics*, **87**: 281–286.

- Snyder, B.D., Polasek, T.M., dan Doogue, M.P., 2012. Drug interactions: Principles and practice. *Australian Prescriber*, **35**: 85–88.
- Sukmana, M. dan Yuniarti, F.A., 2020. The Pathogenesis Characteristics and Symptom of Covid-19 in the Context of Establishing a Nursing Diagnosis. *Jurnal Kesehatan Pasak Bumi Kalimantan*, **3**: 21.
- Tamez-Pérez, H.E., 2015. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. *World Journal of Diabetes*, **6**: 1073.
- Tao, Z., Xu, J., Chen, W., Yang, Z., Xu, X., Liu, L., dkk., 2021. Anemia is associated with severe illness in COVID-19: A retrospective cohort study. *Journal of Medical Virology*, **93**: 1478–1488.
- Taştemur, Ş. dan Ataseven, H., 2020. Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis? *Medical Hypotheses*, **143**: 110018.
- Tatro, D.S., 2015. *Drug Interaction Facts*. Wolters Kluwer Health, United States of America.
- Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., dkk., 2020. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA*, **323**: 1061.
- Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., dkk., 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Research*, **30**: 269–271.
- WHO, 2011. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. *World Health Organization*, 1–6.
- WHO, 2022. Coronavirus disease 2019 (COVID-19):situation report, COVID-19 Weekly Epidemiological Update.
- World Health Organization, 2020. 'Coronavirus disease (COVID-19)', . URL: https://www.who.int/health-topics/coronavirus#tab=tab_1.
- Wu, Z. dan McGoogan, J.M., 2020. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. *JAMA*, **323**: 1239.
- Yuki, K., Fujiogi, M., dan Koutsogiannaki, S., 2020. COVID-19 pathophysiology: A review. *Clinical Immunology*, **215**: 1521–6616.
- Zhao, Y., Harmatz, J.S., Epstein, C.R., Nakagawa, Y., Kurosaki, C., Nakamura, T., dkk., 2015. Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. *British Journal of Clinical Pharmacology*, **80**: 1076–1085.
- Zhou, X., Zhu, J., dan Xu, T., 2020. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin–angiotensin system

inhibitors. *Clinical and Experimental Hypertension*, **42**: 656–660.

Zuin, M., Rigatelli, G., Quadretti, L., Fogato, L., Zuliani, G., dan Roncon, L., 2021.
Prognostic Role of Anemia in COVID-19 Patients: A Meta-Analysis.
Infectious Disease Reports, **13**: 930–937.